Radiation therapy as a backbone of treatment of locally advanced non-small cell lung cancer

Seminars in Oncology

Volumn 41, Issue 1, 2014, Pages 57-68

  Laine, Aaron M ^a   Westover, Kenneth D ^a   Choy, Hak ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; RADIOTHERAPY;

EID: 84894440372     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.12.012     Document Type: Article

References (80)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
2. D.W. Kim, and H. Choy Combined modality therapy for non-small cell lung cancer, past, present, and future Lung Cancer 42 2003 S35 S40
3. D.N. Kim, T.K. Nam, K.S. Choe, and H. Choy Personalized combined modality therapy for locally advanced non-small cell lung cancer Cancer Res Treat 44 2012 74 84
4. K. Basaki, Y. Abe, M. Aoki, H. Kondo, Y. Hatayama, and S. Nakaji Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume Int J Radiat Oncol Biol Phys 64 2006 449 454
5. R.O. Dillman, J. Herndon, S.L. Seagren, W.L. Eaton Jr, and M.R. Green Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial J Natl Cancer Inst 88 1996 1210 1215
6. D.H. Johnson, L.H. Einhorn, and A. Bartolucci et al. Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer Ann Intern Med 113 1990 33 38
7. W.T. Sause, C. Scott, and S. Taylor et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer J Natl Cancer Inst 87 1995 198 205
8. C.A. Perez, M. Bauer, S. Edelstein, B.W. Gillespie, and R. Birch Impact of tumor control on survival in carcinoma of the lung treated with irradiation Int J Radiat Oncol Biol Phys 12 1986 539 547
9. A.T. Pu, A.S. Harrison, J.M. Robertson, J.A. Hayman, M.K. Martel, and R.K. TenHaken The toxicity of elective nodal irradiation in the definitive treatment of non-small cell carcinoma of the lung Int J Radiat Oncol Biol Phys 39 1997 196
10. S. Yuan, X. Sun, and M. Li et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer Am J Clin Oncol Cancer Clin Trials 30 2007 239 244
11. T. Le Chevalier, R. Arriagada, and C. Le Pechoux et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer N Engl J Med 350 2004 351 360
12. J.D. Bradley, J. Moughan, and M.V. Graham et al. A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117 Int J Radiat Oncol Biol Phys 77 2010 367 372
13. J.G. Rosenman, J.S. Halle, and M.A. Socinski et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial Int J Radiat Oncol Biol Phys 54 2002 348 356
14. S.E. Schild, W.L. McGinnis, and D. Graham et al. Results of a phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer Int J Radiat Oncol Biol Phys 65 2006 1106 1111
15. M.A. Socinski, M.J. Schell, and A. Peterman et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer J Clin Oncol 20 2002 1335 1343
16. M. Machtay, R. Paulus, and J. Moughan et al. Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma. A Radiation Therapy Oncology Group analysis J Thorac Oncol 7 2012 716 722
17. Bradley JPR, Komaki R, et al. A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy +/- cetuximab for stage IIIa/IIIb non-small cell lung cancer: preliminary findings on radiation dose in RTOG 0617 (late-breaking abstract 2). 53rd Annual Meeting of the American Society of Radiation Oncology; 2011; Miami, FL.
18. W.J. Curran Jr, R. Paulus, and C.J. Langer et al. Sequential v concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410 J Natl Cancer Inst 103 2011 1452 1460
19. S.E. Schild, P.J. Stella, and S.M. Geyer et al. Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in stage III non-small-cell lung cancer Int J Radiat Oncol Biol Phys 54 2002 370 378
20. M. Saunders, S. Dische, A. Barrett, A. Harvey, D. Gibson, and M. Parmar Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial Lancet 350 1997 161 165
21. C.P. Belani, W. Wang, and D.H. Johnson et al. Phase III study of the eastern cooperative oncology group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer J Clin Oncol 23 2005 3760 3767
22. A. Mauguen, C. Le Pechoux, and M.I. Saunders et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis J Clin Oncol 30 2012 2788 2797
23. K.H. Cho, S.J. Ahn, and H.R. Pyo et al. A phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study Int J Radiat Oncol Biol Phys 74 2009 1397 1404
24. J. Maguire, N. O'Rourke, and C. Peedell et al. Soccar: sequential or concurrent chemotherapy and hypofractionated accelerated radiotherapy in inoperable stage III NSCLC J Thorac Oncol 6 2011 S1561 S1562
25. D.H. Harpole Jr., J.E. Herndon 2nd, W.G. Young Jr., W.G. Wolfe, and D.C. Sabiston Jr Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence Cancer 76 1995 787 796
26. C.R. Kelsey, R.W. Clough, and L.B. Marks Local recurrence following initial resection of NSCLC: salvage is possible with radiation therapy Cancer J 12 2006 283 288
27. W. Sause, P. Kolesar, and S. Taylor et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer - Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group Chest 117 2000 358 364
28. Chemotherapy for non-small cell lung cancer Non-small Cell Lung Cancer Collaborative Group Cochrane Database Syst Rev 2000 CD002139
29. G. Okawara, J.A. Mackay, W.K. Evans, Y.C. Ung Lung Cancer Disease Site Group of Cancer Care Ontario's Program in evidence-based cancer Management of unresected stage III non-small cell lung cancer: a systematic review J Thorac Oncol 1 2006 377 393
30. K. Furuse, M. Fukuoka, and M. Kawahara et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer J Clin Oncol 17 1999 2692 2699
31. N. Hanna, M. Neubauer, and C. Yiannoutsos et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and US Oncology J Clin Oncol 26 2008 5755 5760
32. E.E. Vokes, J.E. Herndon II, and M.J. Kelley et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B J Clin Oncol 25 2007 1698 1704
33. N. Yamamoto, K. Nakagawa, and Y. Nishimura et al. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105 J Clin Oncol 28 2010 3739 3745
34. L. Wang, S. Wu, and G. Ou et al. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer Lung Cancer 77 2012 89 96
35. T. Ciuleanu, T. Brodowicz, and C. Zielinski et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study Lancet 374 2009 1432 1440
36. G. Scagliotti, N. Hanna, and F. Fossella et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies Oncologist 14 2009 253 263
37. J.K. Salama, and E.E. Vokes New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer J Clin Oncol 31 2013 1029 1038
38. C.P. Belani, H. Choy, and P. Bonomi et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol J Clin Oncol 23 2005 5883 5891
39. D.R. Gandara, K. Chansky, and K.S. Albain et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504 J Clin Oncol 21 2003 2004 2010
40. R.M. Huber, W. Engel-Riedel, and J. Kollmeier et al. GILT phase III study: concomitant radiotherapy (RT) with oral vinorelbine (NVBo) plus cisplatin (P) followed by consolidation (C) with NVBo+P plus BSC or BSC alone in stage (st) III NSCLC Onkologie 35 2012 167 168
41. P. Colin, N. Jovenin, and G. Ganem et al. Effect of paclitaxel- carboplatin (PC) consolidation chemotherapy after weekly PC concurrent chemo-radiotherapy (CCR) for patients with locally advanced non-small cell lung cancer (LA-NSCLC): 3-year definitive results of the B001-phase III GERCOR-study J Clin Oncol 24 2006 392S-S
42. K.A. Mason, R. Komaki, J.D. Cox, and L. Milas Biology-based combined-modality radiotherapy: workshop report Int J Radiat Oncol Biol Phys 50 2001 1079 1089
43. P. Huguenin, K.T. Beer, and A. Allal et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy J Clin Oncol 22 2004 4665 4673
44. K. Liang, K.K. Ang, L. Milas, N. Hunter, and Z. Fan The epidermal growth factor receptor mediates radioresistance Int J Radiat Oncol Biol Phys 57 2003 246 254
45. J. Mendelsohn, and Z. Fan Epidermal growth factor receptor family and chemosensitization J Natl Cancer Inst 89 1997 341 343
46. R.K. Schmidt-Ullrich, P. Dent, S. Grant, R.B. Mikkelsen, and K. Valerie Signal transduction and cellular radiation responses Radiat Res 153 2000 245 257
47. J.A. Bonner, P.M. Harari, and J. Giralt et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 2006 567 578
48. G.R. Blumenschein Jr, R. Paulus, and W.J. Curran et al. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324 J Clin Oncol 29 2011 2312 2318
49. R. Govindan, J. Bogart, and T. Stinchcombe et al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B Trial 30407 J Clin Oncol 29 2011 3120 3125
50. P.M. Harari, G.W. Allen, and J.A. Bonner Biology of interactions: antiepidermal growth factor receptor agents J Clin Oncol 25 2007 4057 4065
51. M. Fukuoka, S. Yano, and G. Giaccone et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J Clin Oncol 21 2003 2237 2246
52. M.G. Kris, R.B. Natale, and R.S. Herbst et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - a randomized trial JAMA 290 2003 2149 2158
53. G. Giaccone, R.S. Herbst, and C. Manegold et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT1 J Clin Oncol 22 2004 777 784
54. R.S. Herbst, G. Giaccone, J.H. Schiller, R.B. Natale, and V. Miller Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2 J Clin Oncol 22 2004 785 794
55. T.J. Lynch, D.W. Bell, and R. Sordella et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
56. J.G. Paez, P.A. Janne, and J.C. Lee et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
57. K. Kelly, K. Chansky, and L.E. Gaspar et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023 J Clin Oncol 26 2008 2450 2456
58. N. Ready, P.A. Jaenne, and J. Bogart et al. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis Cancer and Leukemia Group B (CALEB) 30106, a CALGB-stratified phase II trial J Thorac Oncol 5 2010 1382 1390
59. N.W. Choong, A.M. Mauer, and D.J. Haraf et al. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer J Thorac Oncol 3 2008 1003 1011
60. U. Gatzemeier, A. Pluzanska, and A. Szczesna et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial J Clin Oncol 25 2007 1545 1552
61. R.S. Herbst, D. Prager, and R. Hermann et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 2005 5892 5899
62. F.A. Shepherd, J.R. Pereira, and T. Ciuleanu et al. Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
63. P.A. Janne, X. Wang, and M.A. Socinski et al. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial J Clin Oncol 30 2012 2063 2069
64. H.J. Mauceri, N.N. Hanna, and M.A. Beckett et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy Nature 394 1998 287 291
65. R.K. Jain Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 2005 58 62
66. C.G. Willett, Y. Boucher, and E. di Tomaso et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nature Med 10 2004 145 147
67. D.R. Spigel, J.D. Hainsworth, and D.A. Yardley et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab J Clin Oncol 28 2010 43 48
68. N. Raje, and K. Anderson Thalidomide - a revival story N Engl J Med 341 1999 1606 1609
69. T. Hoang, S.E. Dahlberg, and J.H. Schiller et al. Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study J Clin Oncol 30 2012 616 622
70. M. Soda, Y.L. Choi, and M. Enomoto et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 2007 561-U3
71. T. Sasaki, and P.A. Jaenne New strategies for treatment of ALK-rearranged non-small cell lung cancers Clin Cancer Res 17 2011 7213 7218
72. E.H. Romond, E.A. Perez, and J. Bryant et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 2005 1673 1684
73. S. Hellman, and R.R. Weichselbaum Oligometastases J Clin Oncol 13 1995 8 10
74. S. Hellman, and R.R. Weichselbaum Importance of local control in an era of systemic therapy Nat Clin Pract Oncol 2 2005 60 61
75. P.R. Patel, D.S. Yoo, Y. Niibe, J.J. Urbanic, and J.K. Salama A call for the aggressive treatment of oligometastatic and oligo-recurrent non-small cell lung cancer Pulm Med 2012 2012 480961
76. K.S. Corbin, S. Hellman, and R.R. Weichselbaum Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy J Clin Oncol 31 2013 1384 1390
77. N. Mehta, A.M. Mauer, and S. Hellman et al. Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment Int J Oncol 25 2004 1677 1683
78. K.E. Rusthoven, S.F. Hammerman, B.D. Kavanagh, M.J. Birtwhistle, M Stares, and D.R Camidge Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis Acta Oncol 48 2009 578 583
79. Iyengar P, Kavanagh B, Smith I, Ahn C, Gerber D, Dowell J, et. al. A Phase II trial of second-line erlontinib in combination with stereotactic body radiation therapy (SBRT) for patients with metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2013;31:15 suppl:8074
80. J.R. Brahmer Harnessing the immune system for the treatment of non-small-cell lung cancer J Clin Oncol 31 2013 1021 1028